



Integration of a standardized pharmacogenomic platform for clinical decision support at Boston Children's Hospital

Citation

Brownstein, Catherine, Vincent A Fusaro, Sarah Savage, Catherine Clinton, Kenneth Mandl, David Margulies, Wendy Wolf, and Shannon Manzi. 2012. Integration of a standardized pharmacogenomic platform for clinical decision support at Boston Children's Hospital. BMC Proceedings 6(Suppl 6): P5.

Published Version

doi:10.1186/1753-6561-6-S6-P5

Permanent link

<http://nrs.harvard.edu/urn-3:HUL.InstRepos:10522851>

Terms of Use

This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA>

Share Your Story

The Harvard community has made this article openly available.
Please share how this access benefits you. [Submit a story](#).

[Accessibility](#)

POSTER PRESENTATION

Open Access

Integration of a standardized pharmacogenomic platform for clinical decision support at Boston Children's Hospital

Catherine Brownstein^{1*}, Vincent A Fusaro², Sarah Savage¹, Catherine Clinton¹, Kenneth Mandl¹, David Margulies¹, Wendy Wolf¹, Shannon Manzi¹

From Beyond the Genome 2012

Boston, MA, USA. 27-29 September 2012

The Clinical Pharmacogenomics Service (CPS) at Boston Children's Hospital (BCH) was established to use genomic information to make pediatric medications safer. Nearly one-quarter of outpatients are prescribed one or more drugs with genetic information in the FDA label [1]. However, there are still important barriers that must be overcome for routine pharmacogenomic (PGx) clinical use: (1) identification of clinically significant variants, (2) knowledge of variant genotype prior to prescribing medication, and (3) integration with current electronic health record (EHR) systems. To tackle these challenges at BCH, the CPS decided to standardize thiopurine S-methyltransferase (TPMT) testing hospital-wide.

TPMT is best known for its role in the catalyzing the S-methylation of the thiopurine drugs such as azathioprine, 6-mercaptopurine and 6-thioguanine. Approximately 13% of Caucasians and African Americans are heterozygous and have reduced TPMT activity, while approximately 0.3% are completely deficient. Defects in the *TPMT* gene can lead to decreased methylation and excessive levels of the toxic thioguanine nucleotides, particularly with azathioprine and 6-mercaptopurine, and are at risk for bone marrow suppression.

Although the FDA drug label recommends testing for TPMT deficiency prior to dosing and the PharmGKB CPIC group published a guideline [2] with a recommended dosing strategy and interpretation, testing is not universal because these guidelines are difficult to translate into a clinical decision support (CDS) system and integrate with the EHRs. We developed models and specifications to execute PGx CDS rules based on a patient's genotype.

Rules are modeled at four levels of abstraction: (1) unstructured (narrative), (2) semi-structured, (3) structured, and (4) executable.

As genomic sequencing becomes routine, standardized methods to interpret the data and make clinical decisions are paramount. In conjunction with the BCH DNA Diagnostic Laboratory, we streamlined the TPMT testing process to fit into the usual clinical routine (including ordering, testing in-house and return of results to the clinician). We consolidated all genetic sequencing testing into a single clinical workflow (blood to report) that is run, analyzed and interpreted in a Clinical Laboratory Improvement Amendments (CLIA) certified laboratory using the codified CDS rules. The interpretation reports are generated automatically directly from the genotype calls and then manually reviewed for accuracy. Once cleared by the laboratory director, the reports are uploaded into the EHR (Cerner). Specialty flow sheets enable providers to easily view the allele status and interpretation report. We intend to expand the PGx platform to include additional drug/gene pairs.

Author details

¹Boston Children's Hospital, Boston, MA 02115, USA. ²Center for Biomedical Informatics, Harvard Medical School, Boston, MA 02115, USA.

Published: 1 October 2012

References

1. Frueh FW, Amur S, Mummaneni P, Epstein RS, Aubert RE, DeLuca TM, Verbrugge RR, Burckart GJ, Lesko LJ: **Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use.** *Pharmacotherapy* 2008, **28**:992-998.
2. Relling MV, Gardner EE, Sandborn WJ, Schmiegelow K, Pui CH, Yee SW, Stein CM, Carrillo M, Evans WE, Klein TE, Clinical Pharmacogenetics Implementation Consortium: **Clinical Pharmacogenetics Implementation**

¹Boston Children's Hospital, Boston, MA 02115, USA
Full list of author information is available at the end of the article

Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. *Clin Pharmacol Ther* 2011, **89**:387-391.

doi:10.1186/1753-6561-6-S6-P5

Cite this article as: Brownstein *et al.*: Integration of a standardized pharmacogenomic platform for clinical decision support at Boston Children's Hospital. *BMC Proceedings* 2012 **6**(Suppl 6):P5.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

